Electronic Resource
THE #1 IV DRUG REFERENCE FOR 40 YEAR : 2014 INTRAVENOUS MEDICATIONS
Designed to facilitate quick reference, each entry begins with the generic name of the drugin boldface type. Drugs with a Black Box Warning are identified with a symbol in the mainheading. Phonetic pronunciations appear just below the generic name. Drug categories follow. The primary category may be followed by additional ones representing the multipleuses of a drug. Associated trade names are under the generic name. Boldface type and alphabetical order enable the reader to verify correct drug names easily. The use of a Canadian maple leaf symbol ( ) after a trade name indicates availability in Canada only. ThepH is listed in the lower right-hand corner of the title section. While this information is notconsistently available, it is provided whenever possible. It represents the pH of the undiluted drug, the drug after reconstitution, or the drug after dilution for administration.Headings within drug monographs are as follows:Usual Dose: Doses recommended are the usual range for adults unless specifically statedotherwise. This information is presented first to enable the nurse to verify that the physician order is within acceptable parameters while checking the order and before preparation. If there are any questions, much time can be saved in clarifying them. If premedication is indicated, it will be noted here.Pediatric Dose: Pediatric doses are specifically stated if they vary from mg/kg of bodyweight or M2dose recommended for adults. Not all drugs are recommended for use inchildren. See Maternal/Child for information on safety and effectiveness for use in pediatric patients.Infant and/or Neonatal Dose: Included if available and distinct from Pediatric Dose. SeeMaternal/Child for information on safety and effectiveness for use in pediatric patients,including infants and neonates.Dose Adjustments: Any situation that requires increasing or decreasing a dose is mentioned here. The range covers adjustments needed for elderly, debilitated, or hepatic orrenal impairment patients; adjustments required by race or gender; or adjustments required in the presence of other medications or as physical conditions are monitored.
EBK-00220 | 615.1/Bet-t | Perpus Pusat | Tersedia |
Tidak tersedia versi lain